Please use this identifier to cite or link to this item:
|標題:||A combination of the metabolic enzyme inhibitor APO866 and the immune adjuvant L-1-methyl tryptophan induces additive antitumor activity||作者:||Yang, H.J.
|關鍵字:||indoleamine 2,3-dioxygenase;1-methyl tryptophan;APO866 (FK866, WK175);cancer therapy;combination therapy;gastric cancer;bladder cancer;adenine-dinucleotide biosynthesis;plasmacytoid dendritic cells;draining lymph-nodes;indoleamine 2,3-dioxygenase;nad biosynthesis;cancer;angiogenesis;apoptosis;depletion;degradation||Project:||Experimental Biology and Medicine||期刊/報告no：:||Experimental Biology and Medicine, Volume 235, Issue 7, Page(s) 869-876.||摘要:||
Many types of malignant cells have a higher nicotinamide adenine dinucleotide (NAD) turnover rate than normal cells, as well as the ability to escape immune responses. Indoleamine 2,3-dioxygenase (IDO) is reported to be a negative immune regulator. Overexpression of IDO in dendritic cells is observed in tumor-draining lymph nodes. IDO-expressing dendritic cells suppress T-cell activation and promote immune tolerance. The nicotinamide phosphoribosyl transferase (NAMPT) inhibitor APO866 (also called FK866 or WK175) selectively inhibits tumor growth through intracellular NAD depletion. The IDO-specific inhibitor L-1-methyl-tryptophan (L-1MT) activates immune responses and reduces tumor volume in murine tumor models. We combined L-1MT and APO866 treatments and tested their antitumor effects in the murine gastric and bladder tumor models. In immune-competent mice, a combination of APO866 and L-1MT had a better therapeutic effect than did either L-1MT or APO866 alone. The intracellular level of NAD was suppressed by APO866 but not L-1MT. However, an additive inhibitory effect on tumor growth was not observed in tumor-bearing immune-deficient mice. The new strategy of combining a metabolic inhibitor and an immune adjuvant induced a potent therapeutic effect.
|Appears in Collections:||生物醫學研究所|
Show full item record
TAIR Related Article
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.